Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high-risk Stage II and III colon cancers? Three years' follow-up results of the PRODIGE 22 phase II randomized multicentre trial.
Karoui MedhiClaire GalloisGuillaume PiessenJean-Louis LegouxEmilie BarbierCecile De ChaisemartinCedric LecailleOlivier BoucheHanifa AmmarguellatFrancesco BrunettiMichel PrudhommeJean-Marc RegimbeauOlivier GlehenAstrid LievreGuillaume PortierJohannes HartwigGael GoujonBenoit RomainCome LepageJulien Taiebnull nullPublished in: Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland (2021)
Perioperative FOLFOX has no detrimental effect on long-term oncological outcomes and may be an option for some patients with locally advanced CC.
Keyphrases
- phase ii
- locally advanced
- rectal cancer
- clinical trial
- double blind
- open label
- phase iii
- placebo controlled
- neoadjuvant chemotherapy
- phase ii study
- squamous cell carcinoma
- study protocol
- metastatic colorectal cancer
- radiation therapy
- cardiac surgery
- patients undergoing
- randomized controlled trial
- cross sectional
- lymph node
- adipose tissue
- metabolic syndrome
- insulin resistance
- skeletal muscle
- glycemic control